Holen Sie sich die Stockscreener-App
26.45
0.57%
0.15
Handel nachbörslich:
26.50
0.05
+0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.30
Offen:
$26.59
24-Stunden-Volumen:
56.07M
Relative Volume:
1.37
Marktkapitalisierung:
$150.46B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
19.52
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
-0.11%
1M Leistung:
-6.60%
6M Leistung:
+7.48%
1J Leistung:
+10.81%
1-Tages-Spanne:
$26.01
$26.75
1-Wochen-Bereich:
$26.01
$26.91
52-Wochen-Spanne:
$21.97
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.45 | 149.60B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Gains Attention In Russell 1000 Index Momentum - Kalkine Media
Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story - simplywall.st
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC - marketscreener.com
Tunica-Biloxi Tribe receives grant from Pfizer to expand healthcare in Central Louisiana - KLFY.com
Pfizer Oncology Advances Raise New Questions For Valuation And Momentum - Yahoo Finance
Pfizer Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years -- WSJ - Moomoo
Pfizer Earnings: Strong First-Quarter Performance Makes 2026 Guidance More Achievable - Morningstar
BofA raises Pfizer stock price target on first-quarter beat By Investing.com - Investing.com Canada
BofA raises Pfizer stock price target on first-quarter beat - Investing.com
Pfizer CEO Sees CDC Director Pick Restoring Agency’s Credibility - Bloomberg.com
Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid. - Barron's
PFIZER INC : JP Morgan reaffirms its Neutral rating - marketscreener.com
Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms - GuruFocus
Pfizer pins post 2028 return to growth on new obesity and cancer drugs - Yahoo! Finance Canada
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy - Moomoo
Pfizer Q1 2026 slides: beats estimates on acquired assets strength - Investing.com
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - Yahoo Finance
Pfizer tops Q1 expectations on growth from newer products - MSN
Earnings call transcript: Pfizer Q1 2026 beats estimates, stock rises - Investing.com
Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View - Benzinga
Pfizer Q1 Earnings Review: Stuck In Second Gear, But Dividend Helps (NYSE:PFE) - Seeking Alpha
Pfizer : Quarterly Corporate PerformanceFirst Quarter 2026 Presentation - marketscreener.com
Pfizer Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:PFE) 2026-05-05 - Seeking Alpha
Pfizer Tops First-Quarter Estimates, Reaffirms Full-Year Outlook - Moomoo
Pfizer beats first quarter estimates on strong product growth - Investing.com
Pfizer tops sales estimates as older blockbusters outperform - Crain's New York Business
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 29, 2026 - marketscreener.com
Pfizer (PFE) Stock Climbs as Eliquis Drives Strong Q1 Earnings Performance - MEXC
Pfizer (PFE) Stock: Blood Thinner Eliquis Helps Deliver a Clean Q1 Earnings Beat - MEXC Exchange
Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pfizer Posts Better-Than-Expected Revenue, Profit - WSJ
Pfizer Q1 2026 earnings beat estimates on newer drug growth - Yahoo Finance
Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance - Proactive financial news
Pfizer Releases Q1 2026 Financial Results - AlphaStreet
Pfizer posts strong first-quarter earnings, sees boost from recent court wins - Reuters
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Pfizer Q1 Earnings Exceed Expectations - Intellectia AI
Pfizer CEO on his mom not hiding her Holocaust story - CNN
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Australia
Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending - marketscreener.com
Pfizer Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Pfizer Inc. (NYSE:PFE) Tops Q1 2026 Estimates Amid Strong Non-COVID Growth - ChartMill
Pfizer beats first quarter estimates on strong product growth By Investing.com - Investing.com South Africa
Pfizer tops Q1 estimates, maintains guidance (PFE:NYSE) - Seeking Alpha
(PFE) Pfizer Expects 2026 Revenue Range $59.5B to $62.5B, vs. FactSet Est of $61.38B - marketscreener.com
Earnings Flash (PFE) Pfizer Inc. Reports Q1 Revenue $14.45B, vs. FactSet Est of $13.84B - marketscreener.com
Earnings Flash (PFE) Pfizer Inc. Posts Q1 Adjusted EPS $0.75 per Share, vs. FactSet Est of $0.72 - marketscreener.com
Pfizer posts Q1 2026 revenue $14.45B, adjusted diluted EPS $0.75; reaffirms 2026 guidance - TradingView
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - GlobeNewswire Inc.
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):